Sienna Gestion Reduces Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Sienna Gestion decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 95.1% during the third quarter, HoldingsChannel reports. The fund owned 495 shares of the biopharmaceutical company’s stock after selling 9,627 shares during the quarter. Sienna Gestion’s holdings in Regeneron Pharmaceuticals were worth $254,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Salomon & Ludwin LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $31,000. Caitlin John LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $34,000. Traub Capital Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth about $38,000. Finally, Berbice Capital Management LLC lifted its stake in Regeneron Pharmaceuticals by 300.0% in the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 60 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares in the company, valued at $13,860,169.59. This trade represents a 0.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 5,274 shares of company stock valued at $4,142,738. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $759.82 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The firm’s 50 day moving average price is $770.81 and its 200-day moving average price is $689.44. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The company has a market cap of $80.33 billion, a PE ratio of 18.28, a P/E/G ratio of 2.04 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $12.07 earnings per share. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a $0.94 dividend. The ex-dividend date was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.05%.

Analysts Set New Price Targets

Several brokerages have issued reports on REGN. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Scotiabank increased their price target on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a report on Monday, November 24th. Zacks Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price objective for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Finally, Guggenheim upped their price objective on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.